BioWorld Asia

May 18, 2011

View Archived Issues

Parasite Study Challenges Old Thinking on Inflammation

AstraZeneca Declines Option to License BTG's GLP-1 Analogue

EMA Under Fire from European Parliament

Angel Investors Sink $3.6M into Stabilitech's Protein Tech

UK's Biotech, Pharma Groups Continue Collaborative Trend

Other News To Note

Clavis, Translational Therapeutics in Antiviral Drug-for-Equity Deal

Clavis Pharma ASA has gained a small equity stake in Translational Therapeutics Inc. in return for out-licensing its modified version of the antiviral drug ribavirin for applications in cancer. (BioWorld International) Read More

Sanofi Adds Glenmark Antibody to Portfolio for Potential $613M

Today's news in brief

BioWorld

BioWorld briefs for March 26, 2026.

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026